Zimmer Biomet
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) designs, manufactures and markets medical technology for patients with disorders or injuries affecting bones, joints and supporting soft tissues. Its products include knee and hip implants, sports medicine and biologics products, extremities and trauma devices,… From the company’s description.
In fiscal 2025, Zimmer Biomet reported revenue of $8.23B, up 7.2% from fiscal 2024, and net income of $705.10M. Its operating margin was 13.3%, and operations generated $1.70B in cash. Over the twelve months to Jun 30, 2026, revenue was $8.51B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Zimmer Biomet does
In the company’s own words
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) designs, manufactures and markets medical technology for patients with disorders or injuries affecting bones, joints and supporting soft tissues. Its products include knee and hip implants, sports medicine and biologics products, extremities and trauma devices, craniomaxillofacial and thoracic products, bone cement, surgical products, and digital and robotic technologies. The company’s customers include orthopedic and neurosurgeons, other medical specialists, hospitals and ambulatory surgery centers, distributors, dealers and healthcare purchasing organizations. Its product brands include Persona, NexGen, Oxford, Taperloc, G7 and JuggerKnot; its ROSA robots assist surgeons in knee, hip and shoulder procedures, while the ZBEdge platform connects digital and robotic technologies. Zimmer Biomet reports three operating segments: Americas, Europe, Middle East and Africa, and Asia Pacific. Its business traces back to Zimmer Manufacturing Company, founded in 1927; Zimmer Biomet became independent in 2001 and acquired Biomet in 2015. It employed approximately 17,000 people worldwide as of December 31, 2025. Its website is www.zimmerbiomet.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- WARSAW, IN
- Fiscal year end
- December
- CIK
- 1136869
- SIC
- 3842
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Zimmer Biomet — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Zimmer Biomet · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Zimmer Biomet’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Zimmer Biomet’s bonds, as funds hold them
Funds report holding 12 issues of Zimmer Biomet’s debt, $1.15B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.63%, maturing 2026 to 2045.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Zimmer Biomet and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Zimmer Biomet's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Zimmer Biomet's last four quarterly filings that the numbers alone won't show?”